James E. Flynn, Deerfield Management Boost Exposure to Capital Senior Living Corporation
James E. Flynn, the manager of Deerfield Management, disclosed in a new filing, that he together with his fund increased their exposure in Capital Senior Living Corporation (NYSE:CSU). The fund owns over 1.8 million shares, with an aggregate value of $39.6 million, at the current stock price of the company. The position is passive by nature and amasses 6.3% of the outstanding common stock of the company. Deerfield, in its latest 13F, reported around 1.1 million shares of the company. The fund added the company to its equity portfolio during the third quarter.
The stock of Capital Senior Living Corporation rose by around 17% since the beginning of the year. The company holds several senior living communities on the territory of the United States. The company reported an 12.8% appreciation in its revenue in year-on-year terms, which totaled $88 million in the third quarter of the year. The net income of the company amounted to $0.7 million, equal to $0.03 per share, down from $1.8 million in the same period of last year. The Cash From Facility Operations increased by 18% on the year to $8.9 million.
Capital Senior Living purchased two senior living communities during the third quarter paying a total of $21.6 million. Other two communities have been acqured for a combined $31.8 million.
In the latest round of 13F filings, aside from Deerfield, Renaissance Technologies, led by Jim Simons, reported owning 1.3 million shares of the company, slightly up over the quarter. The value of the stakes amounts to $27.7 million. Phill Gross And Robert Atchinson's Adage Capital Management disclosed holding around 1.1 million shares, worth $24.1 million; Joseph Edelman's Perceptive Advisors owns 614,100 shares, with a reported value of $13 million.
Deerfield, in its latest 13F, revealed holding over 5.0 million shares of NxStage Medical, Inc. (NASDAQ:NXTM), the value of the position amounting to $66.2 million, being the largest position in the equity portfolio of the fund. In Array Biopharma Inc (NASDAQ:ARRY), and Pfizer Inc. (NYSE:PFE), James Flynn's fund disclosed $65.8 million, and $51.8 million stakes, which contain 10.6 million and 1.8 million shares respectively.